Personalized Antiplatelet Therapy to Prevent Recurrent Cardiovascular Events in After Ischemic Stroke

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1506 participants.

Also called NCT07943026

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 1,506 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07943026
  • EU CT 2025-523065-16-00
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07943026. Randomized; single masking; primary purpose prevention. Start 2026-12 (anticipated); primary completion 2029-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Personalized Antiplatelet Therapy to Prevent Recurrent Cardiovascular Events in After Ischemic Stroke
Acronym
TAILOR
Intervention (Drug)
Acetylsalicylic acid (ASA)/aspirin 100 mg daily
Intervention (Drug)
Clopidogrel 75 mg daily
Intervention (Drug)
Ticlopidine 250 mg twice daily
Lead sponsor
Azienda Usl di Bologna (class: other government)

Record details

Record id
cardio:ct-nct07943026
Content hash
fd38d24ba523575063d1cff68a555ef0a0498dfe9270b04f35c737e4fda07082